Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.
Featured Documents
6/16/18
A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401
6/16/18
EHA Poster
12/22/17
GIAPREZA™ (angiotensin II) Update

Share Price

Price
Change (%)  (%)
Volume
Data as of

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events
There are currently no events scheduled.
Recent News
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress
11/12/19
SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company  (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced
Read More →
La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference
9/5/19
SAN DIEGO , Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
8/29/19
SAN DIEGO , Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →